Insights into the transcriptomic effects of olaparib response on a breast cancer preclinical model

Abstract

In the past decades, many breast cancer treatments have been approved. Although an effort has been done to identify sensitive patients to specific treatments, such as targeted therapies like poly(ADP-ribose) polymerases (PARP) inhibitors (PARPi), acquired resistances are commonly seen in the clinic. In order to characterize the transcriptional effects of the sensitivity and treatment of the PARP inhibitor olaparib, in this study, we have analysed bulk RNA-seq data of a cohort of patient-derived xenografts (PDX). After assessing the high inter-patient heterogeneity, we perform a differential expression analysis and a functional analysis that reveal an important role of interferons responses in olaparib effect. Finally, we investigate the tumour microenvironment by an immune cell-type deconvolution.